Which tumor marker is more specific for liver cancer?
Total AFP has the sensitivity of 60% and specificity of 90% for the detection of HCC. Increase in the percentage of AFP-L3 over the total AFP (>10%) is very specific for small HCC. PIVKA-II is also more specific than total AFP in detecting HCC.
Which marker is significant in diagnosis of the hepatocellular carcinoma?
α-Fetoprotein remains the most frequently used tumor marker for the diagnosis of HCC.
What is the biomarker for liver cancer?
Alpha-fetoprotein (AFP) is the most widely used biomarker for hepatocellular carcinoma (HCC) during the past several decades. Serum AFP level often diminishes rapidly after birth and remains low throughout adulthood.
What is elevated in hepatocellular carcinoma?
Serum TGF-beta level has been found to be elevated in HCC patients compared to healthy adults or patients with nonmalignant liver disease [25–27].
Is CEA a tumor marker?
CEA is a type of tumor marker. Tumor markers are substances made by cancer cells or by normal cells in response to cancer in the body. A high level of CEA can be a sign of certain types of cancers. These include cancers of the colon and rectum, prostate, ovary, lung, thyroid, or liver.
Is AFP always elevated in hepatocellular carcinoma?
Normal AFP levels are present in as many as 30% of patients at time of diagnosis and usually remain low, even with advanced HCC 39. AFP >400–500 ng/ml is considered diagnostic for HCC, although fewer than half of patients may generate levels that high 39.
What do Tumour markers indicate?
A tumor marker is anything present in or produced by cancer cells or other cells of the body in response to cancer or certain benign (noncancerous) conditions that provides information about a cancer, such as how aggressive it is, what kind of treatment it may respond to, or whether it is responding to treatment.
Is AFP a biomarker?
Serum alpha-fetoprotein (AFP) is by far the most widely used biomarker for HCC screening, early diagnosis, and evaluation of therapeutic efficacy and prognosis (3).